Emiri Grimes is Founder and CEO at Yuimedi, a Japan-based healthtech startup that uses AI to automate medical data preprocessing and enable researchers to create data registries at scale.

Emiri graduated from Kyoto University with a degree in Pharmaceutical Sciences, earned her Master's in Medicinal and Industrial Pharmaceutical Science from ETH Zurich (2016-2018), and worked as a Clinical Research Associate at Takeda and Associate Consultant at McKinsey & Company.

Yuimedi was selected for TechCrunch Startup Battlefield 200 in 2023, joined Alchemist Accelerator 2023 cohort, received $100,000 from Google for Startups Women Founders Fund APAC 2023, and was named Forbes Japan RISING STAR 2022. The company joined Mayo Clinic Platform Accelerate program in 2025.

Yuimedi has raised approximately $5.7M in funding from investors including Coral Capital, Incubate Fund, DG Daiwa Ventures, Nissay Capital, and Chiba Dojo Fund. The company established a US subsidiary with an office in Boston in 2024.

Yuimedi's flagship product Yuicleaner automates data cleansing and standardization, reducing the 60% of time data scientists typically spend on data preparation. The company has partnered with national hospitals and maintains about 10 business partners across the healthcare ecosystem.